Our program offers a large team of providers with specialized expertise in treating all forms of leukemia and lymphoma, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Each year, our leukemia and lymphoma program cares for more than 150 newly diagnosed patients using a variety of treatment protocols, including bone marrow treatment (BMT), and Phase I and II trials for patients whose cancer has relapsed or is not responding to treatment.
Our program includes:
-
Physicians with national Children's Oncology Group (COG) leadership roles and expertise in ALL, AML and Hodgkin lymphoma.
-
Status as one of a select group of centers offering chimeric antigen receptor, CAR T-cell therapy for relapsed leukemia, as well as ongoing research to develop new CAR T-cell technology.
-
Leading a first-in-pediatrics study examining the effects of combining everolimus with other T cell-specific chemotherapy in children with relapsed or refractory.
-
T cell ALL (T-ALL) lymphoblastic lymphoma (LLy) - the goal of the study is to allow more T-ALL/LLy patients to attain remission and proceed to stem cell transplant.
For more information, visit here.
Our leukemia and lymphoma team:
-
Waitman Aumann, MD
-
D. John Bergsagel, MD
-
Kevin Bunting, PhD
-
Sharon Castellino, MD, MSc, Program Director
-
Deb DeRyckere, PhD
-
Douglas Graham, MD, PhD
-
Lubing Gu, MD
-
Curtis Henry, PhD
-
Frank Keller, MD
-
Miyoung Lee, PhD
-
Glen Lew, MD
-
Tamara Miller, MD, MSCE
-
Melinda Pauly, MD
-
Christopher Porter, MD
-
Cheng-Kui Qu, MD, PhD
-
Sunil Raikar, MD
-
Himalee Sabnis, MD, MSc
-
Zhengqi Wang, PhD
-
Daniel Wechsler, MD, PhD
-
William G. Woods, MD
-
Dan Yan, PhD
-
Muxian Zhou, MD